Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HELIOS-B
2024-518318-25-00Phase 3Authorised
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Nov 2024
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 25
01
Overview
Phase 3, randomised, double-blind trial in transthyretin amyloidosis (ATTR) comparing Vutrisiran with Placebo (2 arms). Primary endpoint: Composite outcome of all-cause mortality and recurrent cardiovascular events. Planned start Nov 2024; status: authorised.
02
Drugs
vutrisiran
03
Conditions
transthyretin amyloidosis (ATTR)
Beyond the preview
Go deeper on 2024-518318-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518318-25-00.